Clinical Trial Update: A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of WVE-006 in healthy participants with wild-type alpha-1 antitrypsin expression; results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• WVE-006

Snippet

Sponsor: Wave Life Sciences Ltd. | Conditions: Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1 | Status: COMPLETED | Results posted: 2026-03-23